Vilon

Vilon is a synthetic dipeptide bioregulator composed of lysine and glutamic acid (Lys-Glu), studied as both an immunomodulator and a geroprotective (anti-aging) agent. Its proposed mechanism is unusual: rather than acting on a single receptor, it is thought to reawaken gene expression by decondensing tightly packed chromatin, while also nudging T-cell differentiation and lifting digestive enzyme activity. Researchers have looked at it for cancer therapy, immune support, anti-aging, and improved intestinal function in elderly populations. As with most peptides, it is handled as a research compound requiring reconstitution and injection, where purity and storage are important.

The evidence grade is A-, which sounds strong, but the breakdown deserves scrutiny. It is weighted across 66 peer-reviewed studies, yet only 3 are RCTs; the bulk are 26 animal and 33 in vitro studies, plus 4 reviews. Of 66 classified findings, 54 supported, 9 were mixed, 2 null, and 1 refuting. So while the literature is large and consistently favorable, the human trial base is small, and much of this work comes out of Russian research institutions, which limits independent replication.

What the research shows is intriguing but mostly preclinical. In cultured lymphocytes from elderly people, Vilon decondensed chromatin and reactivated ribosomal genes while leaving structural heterochromatin intact. In female CBA mice, subcutaneous Vilon raised activity and endurance, extended lifespan, and prevented spontaneous tumors without adverse effects. An observational study reported that adding Vilon to cancer treatment improved 2-year survival, reduced post-operative complications, and enhanced quality of life in elderly stage III rectal and colon cancer patients. In thymic cell cultures it increased the CD5 differentiation marker and pushed precursors toward CD4+ helper T-cells. In subjects aged 75-88, it activated ribosomal genes and released age-silenced genes. Oral dosing raised gut enzyme activity in rats, most strongly in 11-month-old animals, and in irradiated rats it supported recovery of thymus and intestinal tissue.

Who should be cautious: anyone combining it with chemotherapy on their own. Combined use with the cytostatic drug cyclophosphamide decreased survival in tumor-bearing mice, so simultaneous use with cytostatic agents is not recommended. Its effects also appear tissue-specific, leaning toward thymic stimulation rather than broad systemic action, so expectations should be tempered.

Community sentiment is minimal: across just 5 community reports, 100% were positive, with anti-aging and longevity support among the mentioned effects, but that sample is far too small to draw conclusions from.

On dosing, animal longevity studies used 1 mg/kg subcutaneously. In oncology settings it was added as an immunomodulator to standard radio- and chemotherapy. Some studies gave it orally for one month to study digestive effects, and tissue-culture work used an effective concentration around 5 ng/ml. Reported benefits skew toward older subjects, where it appears to narrow age-related functional gaps, and animal models suggest post-radiation protection of the thymus and intestine after 6 Gy gamma exposure.

Availability is mostly as a research peptide. It has been studied extensively in Russian medical institutions since the early 2000s and used there in specialized oncology and gerontology settings as adjuvant therapy, and it is manufactured synthetically as Lys-Glu for consistency. The honest summary: a large but largely preclinical and geographically concentrated body of work, with only 3 human RCTs to anchor the bigger claims.